Back to News
Market Impact: 0.35

Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates

OVID
Corporate EarningsCompany FundamentalsAnalyst EstimatesHealthcare & Biotech

Ovid reported quarterly EPS of $0.06, beating the Zacks consensus loss of $0.10 by $0.16 and swinging from a $0.13 loss a year ago (absolute improvement of $0.19). The result is a modest positive catalyst reflecting a move to profitability and could move the shares intraday by a few percent.

Analysis

Ovid reported quarterly EPS of $0.06, beating the Zacks consensus loss of $0.10 by $0.16 and swinging from a $0.13 loss a year ago (absolute improvement of $0.19). The result is a modest positive catalyst reflecting a move to profitability and could move the shares intraday by a few percent.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Demo

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.35

Ticker Sentiment

OVID0.35